Podcast
MSL Talk: Tom Caravela, Chad Fellers
Recruiting for Impact: Inside the Oncology Talent Market
Clips
Summary
Get the real story on oncology recruiting: Michael Pietrack explains the hiring disconnects and strategies behind top-performing executive teams.
Think the best oncology leadership teams just happen?
In this episode of the Oncology Voice Network podcast, host Dr. Kirk Shepard sits down with executive search leader Michael Pietrack for a candid exploration of what really fuels effective executive hiring in oncology drug development.
Discover why time perception differences between candidates and hiring managers often derail the process, how the traditional "buyer and seller" interview dynamic actually works, and why so many companies end up hiring from the same limited pool—risking cultural homogeneity and stunted growth. Michael Pietrack shares how companies can avoid these pitfalls, the signals exec hiring sends to the marketplace, and why siloed decision-making holds organizations back.
From must-know insights on evaluating leadership teams and structuring consensus interviews, to the real-world value of external recruiters and how oncology biotechs are outbidding big pharma for top talent, this episode is loaded with practical, industry-shaping advice.
talent, oncology recruiting, top oncology talent
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Chad Fellers
Podcast
MSL Talk: Tom Caravela, Paula Pearson
How to successfully recruit and hire MSLs VIRTUALLY with Paula Pearson
Article
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
Article
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
Article
iNIZIO